Christopher Shelton, MD
Family Medicine · Irving, TXNPI 1497829618
Payments from drug & device makers
Across 174 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$444
- Johnson & Johnson$284
- GSK$273
- Boehringer Ingelheim$256
- Pfizer$255
- Novo Nordisk$245
- plus $915 from 12 others
What the payments were for
- Food & beverage$2,665100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $444 |
| Johnson & Johnson | 12 | $284 |
| GSK | 20 | $273 |
| Boehringer Ingelheim | 15 | $256 |
| Pfizer | 21 | $255 |
| Novo Nordisk | 18 | $245 |
| Amarin Pharma, Inc. | 10 | $207 |
| Merck | 13 | $163 |
| Sunovion Pharmaceuticals Inc. | 11 | $117 |
| AbbVie(2 entities) | 7 | $114 |
| Astellas Pharma US Inc | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Amgen | 3 | $49 |
| Lilly USA, LLC | 4 | $46 |
| Abbott | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $12 |
How this compares
$2,672 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 85 | $113,495 |
| EliquisApixaban | 109 | $108,181 |
| OzempicSemaglutide | 48 | $63,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $54,452 |
| TrulicityDulaglutide | 16 | $34,975 |
| MyrbetriqMirabegron | 29 | $28,166 |
| XareltoRivaroxaban | 28 | $25,536 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $16,541 |
| MounjaroTirzepatide | 12 | $14,550 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $14,505 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,346 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 236 | $8,135 |
| SynthroidLevothyroxine Sodium | 85 | $8,035 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,354 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $6,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $256 | $113,49585 claims |
| PfizerEliquis | $255 | $108,181109 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $273 | $73,13594 claims |
| Novo NordiskOzempic | $245 | $63,00348 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $46 | $49,52428 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $28,16629 claims |
| Johnson & JohnsonXarelto | $284 | $25,53628 claims |
| MerckJanumet Xr | $163 | $16,54118 claims |
| AstraZenecaSymbicort | $444 | $10,34634 claims |
| AbbVieSynthroid | $114 | $8,03585 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Irving
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.